@article{article, title = {{DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate鈥擜 randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{}}, year = {{2020}}, month = {{2}}, author = {{Niazi T and Williams S and Davis ID and Stockler MR and Martin AJ and Hague W and Bracken K and Gorzeman M and Roncolato F and Yip S and Horvath L et al}}, doi = {{10.1200/jco.2020.38.6_suppl.tps385}}, volume = {{38}}, journal = {{Journal of Clinical Oncology}}, issue = {{6_suppl}}, pages = {{TPS385-TPS385}}, note = {{Accessed on 2025/07/17}}}